Hengrui Pharmaceuticals Expands Overseas Again via NewCo Model, Licensing Cardiac Myosin Inhibitor HRS-1893 to US-Based Braveheart Bio in $1 Bn Deal

Sign In To Get Full Access.

On-the-ground China market intelligence for professionals. Beyond mainstream headlines, cutting through algorithmic noise.

Start Free Now >>>